Neurocrine Biosciences, Inc. Stock price
Equities
NBIX
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.9 USD | +0.07% | -4.05% | +4.68% |
Financials (USD)
Sales 2024 * | 2.21B | Sales 2025 * | 2.52B | Capitalization | 13.72B |
---|---|---|---|---|---|
Net income 2024 * | 492M | Net income 2025 * | 652M | EV / Sales 2024 * | 5.17 x |
Net cash position 2024 * | 2.28B | Net cash position 2025 * | 3.03B | EV / Sales 2025 * | 4.25 x |
P/E ratio 2024 * |
29.4
x | P/E ratio 2025 * |
22
x | Employees | 1,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +0.07% | ||
1 week | -1.94% | ||
Current month | +5.77% | ||
1 month | +1.39% | ||
3 months | +3.89% | ||
6 months | +19.45% | ||
Current year | +4.68% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 227 M€ | +6.28% | - | |
3.81% | 1 M€ | -.--% | - | |
1.85% | 8 M€ | +6.91% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 137.9 | +0.07% | 1,245,663 |
24-03-27 | 137.8 | -2.36% | 1,174,119 |
24-03-26 | 141.2 | +0.65% | 594,739 |
24-03-25 | 140.2 | -0.83% | 535,108 |
24-03-22 | 141.4 | -1.61% | 938,631 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.68% | 13.72B | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+34.25% | 12.22B | |
-6.78% | 10.36B |